These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21232247)

  • 1. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
    Carmeliet P; Collen D
    Trends Cardiovasc Med; 1995; 5(4):117-22. PubMed ID: 21232247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
    Carmeliet P; Collen D
    FASEB J; 1995 Jul; 9(10):934-8. PubMed ID: 7615162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system.
    Carmeliet P; Collen D
    Thromb Haemost; 1995 Jul; 74(1):429-36. PubMed ID: 8578500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological consequences of loss of plasminogen activator gene function in mice.
    Carmeliet P; Schoonjans L; Kieckens L; Ream B; Degen J; Bronson R; De Vos R; van den Oord JJ; Collen D; Mulligan RC
    Nature; 1994 Mar; 368(6470):419-24. PubMed ID: 8133887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the fibrinolytic and matrix metalloproteinase systems in arterial neointima formation after vascular injury.
    Lijnen HR
    Verh K Acad Geneeskd Belg; 2001; 63(6):605-22. PubMed ID: 11813512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
    Shen GX
    Int J Mol Med; 1998 Feb; 1(2):399-408. PubMed ID: 9852242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-specific hemostasis in mice.
    Mackman N
    Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2273-81. PubMed ID: 16123318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice.
    Carmeliet PF
    Baillieres Clin Haematol; 1995 Jun; 8(2):391-401. PubMed ID: 7549069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene manipulation and transfer of the plasminogen and coagulation system in mice.
    Carmeliet P; Collen D
    Semin Thromb Hemost; 1996; 22(6):525-42. PubMed ID: 9122719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmin and matrix metalloproteinases in vascular remodeling.
    Lijnen HR
    Thromb Haemost; 2001 Jul; 86(1):324-33. PubMed ID: 11487021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
    Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
    Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
    Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
    Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of mouse models to study plasminogen activator inhibitor-1.
    Declerck PJ; Gils A; De Taeye B
    Methods Enzymol; 2011; 499():77-104. PubMed ID: 21683250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibrinolytic system in neoplasia.
    Bell WR
    Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
    Chavakis T; Kanse SM; May AE; Preissner KT
    Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.